Brainchip is a genotyping DNAchip which determines the polymorphisms involved in the metabolism of Antipsychotic and Antidepressant drugs. Brainchip predicts drug response to antidepressants and antipsychotics.

1. Biopharma S.L.
Pioneer in the development of personalized medicine for diseases of the nervous system: Neurology and Psychiatry.
Using an innovative scientific and technological methodology, we develop new molecules, as well as diagnostic and
prognostic biomarkers to optimize personalized medicine.
Bibliography:
1. www.healthfirsteurope.org
2. http://www.euro.who.int/en/what-we-do/health-topics/diseases-and-conditions/mental-health.
3. Acute and long-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.
Rush AJ, et al. Am J Pharmacogenomics 2006;163:1905–17.
4. The Promise and Reality of Pharmacogenetics in Psychiatry. Zandi et al. Psychiatr Clin N Am 33 (2010) 181–224.
5. www.brainco.es
October 2010
BRAINco Biopharma S.L.
Edificio 504. Parque Tecnológico de Bizkaia 48160 Derio (Bilbao). Bizkaia. Spain Telf: +34 94 406 45 25 Fax: +34 94 406 45 26
info@brainco.es www.brainco.es
now is possible

2. According to WHO reports, mental disorders are considered one of the main health problems worldwide in terms of What is it?
prevalence, morbidity, mortality, and costs (3 – 4% GDP). (1,2)
Brainchip is a genotyping DNAchip which determines the polymorphisms involved in the metabolism of Antipsychotic
Only 37% of patients suffering from Major Depression reach remission within the first treatment. Treatment and Antidepressant drugs.
non-adherence in patients suffering from Schizophrenia is up to 74% during the first 18 months.(3,4)
The low treatment adherence rate in patients suffering from mental disorders is the main barrier to achieve remission
of symptoms and/or disease. The main reason of treatment non-adherence is the lack of efficacy and/or severity of
How does it work?
adverse reactions. (5)
Genetic variability plays a main role in drug treatment response, particularly, polymorphisms related to drug
Treatment metabolism(5):
non-adherence
Cytochrome P450 (CYP) are the most important Antipsychotic and Antidepressant phase I drug metabolizing
enzymes.
50 % Genetic polymorphisms affect the metabolism of drugs leading to:
50 %
Falta de adherencia
Lack of acy Other reasons
Severe Adverse • Ultrarapid Metabolizers (UM): Enzymatic activity is increased. Drug plasma levels are lower than
Reactions normal conditions. Lack of efficacy.
Exacerbations
Hospital admissions • Poor Metabolizers (PM): Enzymatic activity is decreased. Drug plasma levels are higher than normal
Increase in costs conditions. Risk of adverse reactions.
Brainchip predicts Antipsychotics and Antidepressants treatment response, helping MD to prescribe the
best treatment for each patient: PERSONALIZED MEDICINE.
Needs:
Predict treatment response. How does it help?
Increase treatment efficacy and safety. Increases levels of effectiveness.
Reduce costs. Increases levels of security.
Reduces the costs of the disease.
Pharmacogenetics helps to predict individual Brainchip
response to drug treatment.
Poor Metabolizer Normal Metabolizer Ultrarapid Metabolizer
Toxicity Lack of E cacy
Treatment selection:
Increase E cacy
Increase Safety
Reduce Costs
Brainchip is an open tool in continuous improvement process which allows midterm further applications.
“The aim of speculative science is the truth; the aim of
practical science is action”
Aristotle